Biotech Co.* | Pharma Co. | Product | Terms/Details (Date) |
| | |||
Cepheid Inc. | Izasa SA (Spain) | Cepheid Smart Cycler system | Multiyear distribution agreement to market the Cepheid Smart Cycler system, accessories and disposable reaction tubes in Spain, Portugal, Italy, Austria, France, the Netherlands and the UK; Izasa will provide marketing sales and service support (5/28) |
Guilford Pharmaceuticals | Orphan Australia Pt. Ltd. (Australia) | Gliadel Wafer | Orphan gained exclusive rights to market, sell and distribute Guilford's brain cancer therapy in Australia and New Zealand (6/6) |
Hemispherx | Laboratorios Del Dr. Esteve SA (Spain) | Various products | The companies will collaborate in areas related to sales and distribution, and the initiation and conducting of specific clinical trials (6/5) |
NeoTherapeutics | J.B. Chemicals & Pharmaceuticals Ltd. (India) | J.B. Chemicals' products through a joint venture called NeoJB LLC | NeoTherapeutics will own 80% of NeoJB, and a J.B. Chemicals subsidiary will own the rest; the joint venture was formed to enable NeoTherapeutics to benefit from J.B. Chemicals' lower-cost drug manufacturing capabilities and from the sale of J.B. Chemicals' products in the U.S. (5/1) |
SkyePharma plc | Shire Pharmaceuticals Group plc (UK) | Solaraze | Shire gains rights to Solaraze in Europe for up to 15M (US$21.9M); SkyePharma will receive royalties on all European sales (5/13) |
Strakan Group | Fujisawa GmbH (subsidiary of Fujisawa Pharmaceutical Co. Ltd.; Japan) | Zindaclin | Agreement granting Fujisawa exclusive marketing rights to Zindaclin for continental Europe (5/29) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange | |||
